{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Triple+Negative&page=2", "query": { "condition": "Triple Negative", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Triple+Negative&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-06-11T09:53:02.097Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06657222", "title": "First in Human Study of TUB-030 in Patients With Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumors", "HNSCC", "SCLC", "NSCLC", "TNBC - Triple-Negative Breast Cancer", "CRC" ], "interventions": [ { "name": "TUB-030", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tubulis GmbH", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 250, "start_date": "2024-12-13", "completion_date": "2028-12", "has_results": false, "last_update_posted_date": "2026-05-27", "last_synced_at": "2026-06-11T09:53:02.097Z", "location_count": 12, "location_summary": "New Haven, Connecticut • Miami, Florida • Boston, Massachusetts + 9 more", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "Miami", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT06657222" }, { "nct_id": "NCT02208375", "title": "mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "BRCA1 Mutation Carrier", "BRCA2 Mutation Carrier", "Endometrial Adenocarcinoma", "Estrogen Receptor Negative", "HER2/Neu Negative", "High Grade Ovarian Serous Adenocarcinoma", "Progesterone Receptor Negative", "Recurrent Breast Carcinoma", "Recurrent Fallopian Tube Carcinoma", "Recurrent Ovarian Carcinoma", "Recurrent Primary Peritoneal Carcinoma", "Recurrent Uterine Corpus Carcinoma", "Stage III Uterine Corpus Cancer AJCC v7", "Stage IV Breast Cancer AJCC v6 and v7", "Stage IV Uterine Corpus Cancer AJCC v7", "Triple-Negative Breast Carcinoma" ], "interventions": [ { "name": "Capivasertib", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Olaparib", "type": "DRUG" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Vistusertib", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 159, "start_date": "2014-11-11", "completion_date": "2026-06-30", "has_results": false, "last_update_posted_date": "2025-12-31", "last_synced_at": "2026-06-11T09:53:02.097Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02208375" }, { "nct_id": "NCT06974604", "title": "Preventing Dato-DXd Associated Stomatitis With Dexamethasone Mouthwash, TROPION-DM", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Neoplasms", "Lung Neoplasms" ], "interventions": [ { "name": "Dexamethasone oral", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Brown University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2025-10-22", "completion_date": "2029-05-31", "has_results": false, "last_update_posted_date": "2025-10-24", "last_synced_at": "2026-06-11T09:53:02.097Z", "location_count": 1, "location_summary": "Providence, Rhode Island", "locations": [ { "city": "Providence", "state": "Rhode Island" } ], "official_url": "https://clinicaltrials.gov/study/NCT06974604" }, { "nct_id": "NCT02993068", "title": "Stand up to Cancer: MAGENTA (Making Genetic Testing Accessible)", "overall_status": "SUSPENDED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "BARD1 Gene Mutation", "BRCA1 Gene Mutation", "BRCA2 Gene Mutation", "BRIP1 Gene Mutation", "Estrogen Receptor Negative", "HER2/Neu Negative", "MLH1 Gene Mutation", "MSH2 Gene Mutation", "MSH6 Gene Mutation", "PALB2 Gene Mutation", "PMS2 Gene Mutation", "Progesterone Receptor Negative", "RAD51C Gene Mutation", "RAD51D Gene Mutation", "Triple-Negative Breast Carcinoma" ], "interventions": [ { "name": "Educational Intervention", "type": "OTHER" }, { "name": "Genetic Counseling", "type": "OTHER" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "30 Years", "maximum_age": null, "sex": "FEMALE", "summary": "30 Years and older · Female only" }, "enrollment_count": 5200, "start_date": "2017-04-18", "completion_date": "2026-04-18", "has_results": false, "last_update_posted_date": "2026-02-19", "last_synced_at": "2026-06-11T09:53:02.097Z", "location_count": 2, "location_summary": "Houston, Texas • Seattle, Washington", "locations": [ { "city": "Houston", "state": "Texas" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT02993068" }, { "nct_id": "NCT04442126", "title": "A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumor", "Non-small Cell Lung Cancer", "Colorectal Cancer", "Squamous Cell Carcinoma", "Ovarian Carcinoma", "Peritoneal Carcinoma", "Fallopian Tube Cancer", "Head and Neck Squamous Cell Carcinoma", "Triple Negative Breast Cancer" ], "interventions": [ { "name": "NM21-1480", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Numab Therapeutics AG", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 52, "start_date": "2020-08-19", "completion_date": "2024-02-06", "has_results": true, "last_update_posted_date": "2025-05-23", "last_synced_at": "2026-06-11T09:53:02.097Z", "location_count": 14, "location_summary": "Fort Collins, Colorado • Augusta, Georgia • New Orleans, Louisiana + 11 more", "locations": [ { "city": "Fort Collins", "state": "Colorado" }, { "city": "Augusta", "state": "Georgia" }, { "city": "New Orleans", "state": "Louisiana" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Ypsilanti", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT04442126" }, { "nct_id": "NCT03256344", "title": "Study of Talimogene Laherparepvec With Atezolizumab for Triple Negative Breast Cancer and Colorectal Cancer With Liver Metastases", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Triple Negative Breast Cancer", "Metastatic Colorectal Cancer" ], "interventions": [ { "name": "Talimogene Laherparepvec", "type": "BIOLOGICAL" }, { "name": "Atezolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 36, "start_date": "2018-03-19", "completion_date": "2021-12-03", "has_results": true, "last_update_posted_date": "2024-05-14", "last_synced_at": "2026-06-11T09:53:02.097Z", "location_count": 3, "location_summary": "Los Angeles, California • New York, New York • Stony Brook, New York", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "New York", "state": "New York" }, { "city": "Stony Brook", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03256344" }, { "nct_id": "NCT02926690", "title": "Safety Study of MELK Inhibitor to Treat Patients With Advanced Breast Cancer and Triple Negative Breast Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Relapsed/Refractory Locally Advanced or Metastatic Breast Cancer and Triple Negative Breast Cancer" ], "interventions": [ { "name": "OTS167PO", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "OncoTherapy Science, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 70, "start_date": "2017-05-29", "completion_date": "2027-09", "has_results": false, "last_update_posted_date": "2026-02-25", "last_synced_at": "2026-06-11T09:53:02.097Z", "location_count": 8, "location_summary": "Norwalk, Connecticut • Atlanta, Georgia • Honolulu, Hawaii + 4 more", "locations": [ { "city": "Norwalk", "state": "Connecticut" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Honolulu", "state": "Hawaii" }, { "city": "Lebanon", "state": "New Hampshire" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02926690" }, { "nct_id": "NCT04243616", "title": "Cemiplimab in High-risk or Locally Advanced Luminal and Triple Negative Breast Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Invasive Breast Cancer" ], "interventions": [ { "name": "Cemiplimab", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Carboplatin (not mandatory)", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Medical College of Wisconsin", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 36, "start_date": "2020-03-05", "completion_date": "2030-08-12", "has_results": false, "last_update_posted_date": "2025-09-05", "last_synced_at": "2026-06-11T09:53:02.097Z", "location_count": 1, "location_summary": "Milwaukee, Wisconsin", "locations": [ { "city": "Milwaukee", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT04243616" }, { "nct_id": "NCT03387085", "title": "QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy.", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Triple Negative Breast Cancer" ], "interventions": [ { "name": "Aldoxorubicin HCl", "type": "DRUG" }, { "name": "N-803", "type": "BIOLOGICAL" }, { "name": "ETBX-011", "type": "BIOLOGICAL" }, { "name": "ETBX-051", "type": "BIOLOGICAL" }, { "name": "ETBX-061", "type": "BIOLOGICAL" }, { "name": "GI-4000", "type": "BIOLOGICAL" }, { "name": "GI-6207", "type": "BIOLOGICAL" }, { "name": "GI-6301", "type": "BIOLOGICAL" }, { "name": "haNK for Infusion", "type": "BIOLOGICAL" }, { "name": "avelumab", "type": "BIOLOGICAL" }, { "name": "bevacizumab", "type": "BIOLOGICAL" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "5-Fluorouracil", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "nab-Paclitaxel", "type": "DRUG" }, { "name": "SBRT", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "PROCEDURE" ], "sponsor": "ImmunityBio, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 9, "start_date": "2018-03-19", "completion_date": "2024-01-16", "has_results": true, "last_update_posted_date": "2024-08-09", "last_synced_at": "2026-06-11T09:53:02.097Z", "location_count": 1, "location_summary": "El Segundo, California", "locations": [ { "city": "El Segundo", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03387085" }, { "nct_id": "NCT01289353", "title": "Concurrent Adjuvant Carboplatin and Accelerated Radiotherapy for Triple Negative Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Carboplatin", "type": "DRUG" }, { "name": "3D-RT or IMRT", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "NYU Langone Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 92, "start_date": "2009-03-06", "completion_date": "2019-07-08", "has_results": true, "last_update_posted_date": "2021-01-12", "last_synced_at": "2026-06-11T09:53:02.097Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01289353" } ] }